Adverse skin reaction to Secukinumab

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disorder affecting about 1 to 3% of the population worldwide (1). The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including TNF-a inhibitors and interleukin (IL) 12/23 and 17 inhibitors. In 2015, secukinumab was the first IL-17A inhibitor approved for the treatment of moderate-to-severe psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis (2). We report a severe cutaneous reaction to secukinumab that required termination of therapy in a patient non-responder to all biologic drugs approved for the treatment of psoriasis.

This article is protected by copyright. All rights reserved.

http://ift.tt/2ohNZHF